Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
Z.A. Wainberg(University of California, Los Angeles), J. Randolph Hecht(University of California, Los Angeles)
Cited by 85